Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 10 902 M
EBIT 2016 3 288 M
Net income 2016 2 070 M
Debt 2016 10 187 M
Yield 2016 -
Sales 2017 13 200 M
EBIT 2017 4 228 M
Net income 2017 2 722 M
Debt 2017 9 938 M
Yield 2017 -
P/E ratio 2016 12,95
P/E ratio 2017 10,02
EV / Sales2016 3,11x
EV / Sales2017 2,55x
Capitalization 23 751 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted primarily in the U.S. and... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/27 MYLAN NV : Receives U.S. FTC Clearance for Proposed Meda Acquisition
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
07/21 MYLAN NV : Publishes Supplement to Meda Offer Document
07/21 MYLAN NV : and Biocon Announce Regulatory Submission for Proposed Biosimilar Peg..
07/20DJMYLAN NV : EU Approves Mylan's $7.2 Billion Acquisition of Meda
07/20 MYLAN NV : Launches Generic Crestor® Tablets
07/20 MEDA : Mylan gets EU approval for Meda purchase, subject to conditions
07/20DJAbbott Labs Profit Tops Views
07/15 EXCLUSIVE - MYLAN TO GET EU GREEN LI : sources
More news
Sector news : Pharmaceuticals - NEC
10:54aDJSANOFI : Profit Down as Diabetes Drug Sales Slip--Update
08:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07:45aDJSANOFI : Profit Down as Diabetes Drug Sales Slip
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 58,1 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%23 751
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
More Results